title: Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats.
abstract: We have studied the possible interaction between three selective opioid-receptor antagonists, nor-binaltorphimine (NB: kappa) (5 mg/kg), cyprodime (CY: mu) (10 mg/kg) and naltrindole (NTI: delta) (1 mg/kg), and the cannabinoid receptor agonist CP 55,940, in the modulation of anxiety (plus-maze) and adrenocortical activity (serum corticosterone levels by radioimmunoassay) in male rats. The holeboard was used to evaluate motor activity and directed exploration. CP 55,940 (75 microg/kg, but not 10 microg/kg) induced an anxiogenic-like effect, which was antagonised by NB. The other effects of CP 55,940 (75 microg/kg), a decreased holeboard activity and stimulation of adrenocortical activity, were not antagonised by any of the three opioid receptor antagonists. CY and NTI, when administered alone, induced marked reductions in motor activity, anxiogenic-like effects and stimulation of adrenocortical activity. The selective kappa-opioid receptor antagonist NB, on its own, did not modify the level of anxiety but stimulated adrenocortical activity. We provide the first pharmacological evidence about the involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55,940.
authors.affiliation: Departamento de Biología Animal II (Fisiologi;a Animal), Facultad de Biología, Universidad Complutense, 28040-, Madrid, Spain.
authors.forename: S
authors.initials: S
authors.lastname: Marín
authors.forename: E
authors.initials: E
authors.lastname: Marco
authors.forename: M
authors.initials: M
authors.lastname: Biscaia
authors.forename: B
authors.initials: B
authors.lastname: Fernández
authors.forename: M
authors.initials: M
authors.lastname: Rubio
authors.forename: C
authors.initials: C
authors.lastname: Guaza
authors.forename: H
authors.initials: H
authors.lastname: Schmidhammer
authors.forename: M P
authors.initials: MP
authors.lastname: Viveros
mesh_terms: D000818:Animals; D001007:Anxiety / Q000097:blood / Q000139:chemically induced*; D002186:Cannabinoids / Q000494:pharmacology*; D003345:Corticosterone / Q000097:blood; D003511:Cyclohexanols / Q000494:pharmacology*; D008297:Male; D018782:Maze Learning / Q000187:drug effects / Q000502:physiology; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D009292:Narcotic Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D017473:Receptors, Opioid, kappa / Q000819:agonists / Q000037:antagonists & inhibitors / Q000502:physiology*
chemical_list: D002186:Cannabinoids; D003511:Cyclohexanols; D009292:Narcotic Antagonists; D017473:Receptors, Opioid, kappa; C054649:3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol; D003345:Corticosterone